Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Theralase Technologies Inc (TSXV:TLT) has been granted a U.S. patent for Multiwavelength Photodynamic Therapy (PDT) technology.
  • The patent will allow Theralase to use technology that may be help destroy large and/or deep-seated tumours.
  • The company expects that the patent will increase the company’s value.
  • Theralase Technologies’ share price is down 4.84 per cent, with shares trading at $0.30 apiece.

Pharmaceutical company Theralase Technologies Inc (TLT), has been granted a U.S. patent for Multiwavelength PhotoDynamic Therapy (PDT) technology.

The patent is entitled “Apparatus and Method for Multiwavelength Photodynamic Therapy”.

The patent grant will allow Theralase to use technology that may target and destroy large and/or deep-seated cancerous tumours more effectively.

The technology involves using various laser wavelengths to activate PhotoDynamic Compounds (PDC) in tumours.

The use of one particular laser wavelength often only partially destroys large and/or deep-seated tumours. However, the addition one or two more laser wavelengths may completely and safely destroy the tumours.

This is because different laser wavelengths can penetrate different tissue depths. Scientists believe that this will greatly aid in combatting cancers such as Glio Blastoma Multiform (GBM) and Non-Small Cell Lung Cancer (NSCLC).

Theralase’s Chief Scientific Officer, Dr Arkady Mandel M.D., Ph.D., D.Sc., predicts that the U.S. patent will increase company value.

The company’s comprehensive intellectual property portfolio will also continue to strengthen their position in the global oncology market.

Theralase Technologies’ share price is down 4.84 per cent, with shares trading at $0.30 apiece.

More From The Market Herald
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK MHRA.

" Telo Genomics (TSXV:TELO) advances lead product and Implements automation to workflow

Telo Genomics (TELO) has announced a study for its lead product for smoldering multiple myeloma (SMM) patients and completed research and development projects.

" Cardiol Therapeutics (TSX:CRDL) appoints leaders in cardiovascular medicine to scientific advisory board

Cardiol Therapeutics (CRDL) has appointed Dr. Paul M. Ridker, Dr. Bruce McManus, and Dr. Joseph A. Hill to its scientific advisory board.